Investor Relations

Investor Relations

Corporate Profile

Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders. We commercialize a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets.

Our prescription WatchPAT family of products, which utilizes the PAT signal, is designed to enable patients suspected to have sleep related breathing disorders to easily conduct sleep apnea tests in the comfort of their homes in accordance with a physician’s instructions, as authorized by qualified medical personnel while delivering the treating physicians with comprehensive, accurate and reliable results to aid in the diagnosis of sleep apnea.

 
Stock Information
Press Releases
Jan
2021
Itamar Medical Acquires Technology and Assets of Spry Health
Jan
2021
Itamar Medical Acquires Technology and Assets of Spry Health
Jan
2021
Itamar Medical Announces Preliminary Revenue Results for Fourth Quarter and Full Year 2020
Dec
2020
Itamar Medical Announces Additional 16 Million Covered Lives for WatchPAT™, the Only Single-Use Sleep Apnea Test that Meets Guidelines
Dec
2020
Itamar Medical Comments on U.S. Centers for Medicare & Medicaid Services (CMS) 2021 Fee Schedule with Reimbursement Update for Home Sleep Apnea Testing
Dec
2020
Itamar Medical Announces Results from Multi-Center Study Validate Use of WatchPAT™ in Diagnosing Sleep Apnea in Patients with AFib
Investor Events
Nov
2020
Piper Virtual Healthcare Conference
Nov
2020
Q3 2020 Itamar Medical Ltd. Earnings Conference Call
Sep
2020
H.C. Wainwright 22nd Annual Global Investment Conference
Aug
2020
Notice of annual shareholders meeting
Investor Presentations
Management